Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 91 entries
Sorted by: Best Match Show Resources per page
Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine.

Proceedings (Baylor University. Medical Center)

Hundemer GL, Fenves AZ.
PMID: 28405069
Proc (Bayl Univ Med Cent). 2017 Apr;30(2):169-170. doi: 10.1080/08998280.2017.11929570.

Acquired 5-oxoprolinemia is increasingly recognized as a cause of anion gap metabolic acidosis. It predominantly occurs in chronically ill, malnourished women with impaired renal function and chronic acetaminophen ingestion. Depletion of glutathione and cysteine stores leads to elevated 5-oxoproline...

Cite
Hundemer GL, Fenves AZ. Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine. Proc (Bayl Univ Med Cent). 2017;30(2):169-170doi: 10.1080/08998280.2017.11929570.
Hundemer, G. L., & Fenves, A. Z. (2017). Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine. Proceedings (Baylor University. Medical Center), 30(2), 169-170. https://doi.org/10.1080/08998280.2017.11929570
Hundemer, Gregory L, and Fenves, Andrew Z. "Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine." Proceedings (Baylor University. Medical Center) vol. 30,2 (2017): 169-170. doi: https://doi.org/10.1080/08998280.2017.11929570
Hundemer GL, Fenves AZ. Acquired 5-oxoproline acidemia successfully treated with N-acetylcysteine. Proc (Bayl Univ Med Cent). 2017 Apr;30(2):169-170. doi: 10.1080/08998280.2017.11929570. PMID: 28405069; PMCID: PMC5349815.
Copy Download .nbib Format: NLM
OBO-Fused Benzo[fg]tetracene as Acceptor With Potential for Thermally Activated Delayed Fluorescence Emitters.

Frontiers in chemistry

Zhang Z, Kumar S, Bagnich S, Spuling E, Hundemer F, Nieger M, Hassan Z, Köhler A, Zysman-Colman E, Bräse S.
PMID: 33195051
Front Chem. 2020 Sep 30;8:563411. doi: 10.3389/fchem.2020.563411. eCollection 2020.

Six luminophores bearing an OBO-fused benzo[fg]tetracene core as an electron acceptor were designed and synthesized. The molecular structures of three molecules (PXZ-OBO, 5PXZ-OBO, 5DMAC-OBO) were determined by single crystal X-ray diffraction studies and revealed significant torsion between the donor...

Cite
Zhang Z, Kumar S, Bagnich S, et al. OBO-Fused Benzo[fg]tetracene as Acceptor With Potential for Thermally Activated Delayed Fluorescence Emitters. Front Chem. 2020;8:563411doi: 10.3389/fchem.2020.563411.
Zhang, Z., Kumar, S., Bagnich, S., Spuling, E., Hundemer, F., Nieger, M., Hassan, Z., Köhler, A., Zysman-Colman, E., & Bräse, S. (2020). OBO-Fused Benzo[fg]tetracene as Acceptor With Potential for Thermally Activated Delayed Fluorescence Emitters. Frontiers in chemistry, 8563411. https://doi.org/10.3389/fchem.2020.563411
Zhang, Zhen, et al. "OBO-Fused Benzo[fg]tetracene as Acceptor With Potential for Thermally Activated Delayed Fluorescence Emitters." Frontiers in chemistry vol. 8 (2020): 563411. doi: https://doi.org/10.3389/fchem.2020.563411
Zhang Z, Kumar S, Bagnich S, Spuling E, Hundemer F, Nieger M, Hassan Z, Köhler A, Zysman-Colman E, Bräse S. OBO-Fused Benzo[fg]tetracene as Acceptor With Potential for Thermally Activated Delayed Fluorescence Emitters. Front Chem. 2020 Sep 30;8:563411. doi: 10.3389/fchem.2020.563411. eCollection 2020. PMID: 33195051; PMCID: PMC7555999.
Copy Download .nbib Format: NLM
Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters.

Kidney international reports

Hundemer GL, Sood MM.
PMID: 31080915
Kidney Int Rep. 2019 Mar 20;4(5):635-637. doi: 10.1016/j.ekir.2019.03.010. eCollection 2019 May.

No abstract available.

Cite
Hundemer GL, Sood MM. Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters. Kidney Int Rep. 2019;4(5):635-637doi: 10.1016/j.ekir.2019.03.010.
Hundemer, G. L., & Sood, M. M. (2019). Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters. Kidney international reports, 4(5), 635-637. https://doi.org/10.1016/j.ekir.2019.03.010
Hundemer, Gregory L, and Sood, Manish M. "Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters." Kidney international reports vol. 4,5 (2019): 635-637. doi: https://doi.org/10.1016/j.ekir.2019.03.010
Hundemer GL, Sood MM. Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters. Kidney Int Rep. 2019 Mar 20;4(5):635-637. doi: 10.1016/j.ekir.2019.03.010. eCollection 2019 May. PMID: 31080915; PMCID: PMC6506708.
Copy Download .nbib Format: NLM
100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021.

Journal of inherited metabolic disease

Ramoser G, Caferri F, Radlinger B, Brunner-Krainz M, Herbst S, Huemer M, Hufgard-Leitner M, Kircher SG, Konstantopoulou V, Löscher W, Möslinger D, Plecko B, Spenger J, Stulnig T, Sunder-Plassmann G, Wortmann S, Scholl-Bürgi S, Karall D.
PMID: 34595757
J Inherit Metab Dis. 2021 Sep 30; doi: 10.1002/jimd.12442. Epub 2021 Sep 30.

Inherited metabolic disorders (IMDs) are a heterogeneous group of rare disorders characterized by disruption of metabolic pathways. To date, data on incidence and prevalence of IMDs are limited. Taking advantage of a functioning network within the Austrian metabolic group,...

Cite
Ramoser G, Caferri F, Radlinger B, et al. 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. J Inherit Metab Dis. 2021;doi: 10.1002/jimd.12442.
Ramoser, G., Caferri, F., Radlinger, B., Brunner-Krainz, M., Herbst, S., Huemer, M., Hufgard-Leitner, M., Kircher, S. G., Konstantopoulou, V., Löscher, W., Möslinger, D., Plecko, B., Spenger, J., Stulnig, T., Sunder-Plassmann, G., Wortmann, S., Scholl-Bürgi, S., Karall, D. (2021). 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. Journal of inherited metabolic disease, . https://doi.org/10.1002/jimd.12442
Ramoser, Gabriele, et al. "100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021." Journal of inherited metabolic disease vol. (2021). doi: https://doi.org/10.1002/jimd.12442
Ramoser G, Caferri F, Radlinger B, Brunner-Krainz M, Herbst S, Huemer M, Hufgard-Leitner M, Kircher SG, Konstantopoulou V, Löscher W, Möslinger D, Plecko B, Spenger J, Stulnig T, Sunder-Plassmann G, Wortmann S, Scholl-Bürgi S, Karall D. 100 years of inherited metabolic disorders in Austria-A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021. J Inherit Metab Dis. 2021 Sep 30; doi: 10.1002/jimd.12442. Epub 2021 Sep 30. PMID: 34595757.
Copy Download .nbib Format: NLM
AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

Cancers

Schubert M, Gassner FJ, Huemer M, Höpner JP, Akimova E, Steiner M, Egle A, Greil R, Zaborsky N, Geisberger R.
PMID: 34073525
Cancers (Basel). 2021 May 26;13(11). doi: 10.3390/cancers13112619.

Adaptive somatic mutations conferring treatment resistance and accelerated disease progression is still a major problem in cancer therapy. Additionally in CLL, patients receiving novel, efficient drugs frequently become treatment refractory and eventually relapse. Activation-induced deaminase (AID) is a cytosine...

Cite
Schubert M, Gassner FJ, Huemer M, et al. AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. Cancers (Basel). 2021;13(11)doi: 10.3390/cancers13112619.
Schubert, M., Gassner, F. J., Huemer, M., Höpner, J. P., Akimova, E., Steiner, M., Egle, A., Greil, R., Zaborsky, N., & Geisberger, R. (2021). AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. Cancers, 13(11), . https://doi.org/10.3390/cancers13112619
Schubert, Maria, et al. "AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL." Cancers vol. 13,11 (2021). doi: https://doi.org/10.3390/cancers13112619
Schubert M, Gassner FJ, Huemer M, Höpner JP, Akimova E, Steiner M, Egle A, Greil R, Zaborsky N, Geisberger R. AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. Cancers (Basel). 2021 May 26;13(11). doi: 10.3390/cancers13112619. PMID: 34073525; PMCID: PMC8198502.
Copy Download .nbib Format: NLM
Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines.

JIMD reports

Häberle J, Huemer M.
PMID: 25690729
JIMD Rep. 2015;21:65-70. doi: 10.1007/8904_2014_387. Epub 2015 Feb 18.

BACKGROUND: Implementation of guidelines and assessment of their adaptation is not an extensively investigated process in the field of rare diseases. However, whether targeted recipients are reached and willing and able to follow the recommendations has significant impact on...

Cite
Häberle J, Huemer M. Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines. JIMD Rep. 2015;21:65-70doi: 10.1007/8904_2014_387.
Häberle, J., & Huemer, M. (2015). Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines. JIMD reports, 2165-70. https://doi.org/10.1007/8904_2014_387
Häberle, Johannes, and Huemer, Martina. "Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines." JIMD reports vol. 21 (2015): 65-70. doi: https://doi.org/10.1007/8904_2014_387
Häberle J, Huemer M. Evaluation of Implementation, Adaptation and Use of the Recently Proposed Urea Cycle Disorders Guidelines. JIMD Rep. 2015;21:65-70. doi: 10.1007/8904_2014_387. Epub 2015 Feb 18. PMID: 25690729; PMCID: PMC4470941.
Copy Download .nbib Format: NLM
A Synthesis of Substituted α-Allenols via Iron-Catalyzed Cross-Coupling of Propargyl Carboxylates with Grignard Reagents.

ACS catalysis

Kessler SN, Hundemer F, Bäckvall JE.
PMID: 27840771
ACS Catal. 2016 Nov 04;6(11):7448-7451. doi: 10.1021/acscatal.6b02114. Epub 2016 Sep 28.

α-Allenols are attractive and versatile compounds whose preparation can be a nontrivial task. In this Letter, we provide a method for the prompt synthesis of substituted α-allenols via a catalytic cross-coupling reaction which makes use of a nontoxic and...

Cite
Kessler SN, Hundemer F, Bäckvall JE. A Synthesis of Substituted α-Allenols via Iron-Catalyzed Cross-Coupling of Propargyl Carboxylates with Grignard Reagents. ACS Catal. 2016;6(11):7448-7451doi: 10.1021/acscatal.6b02114.
Kessler, S. N., Hundemer, F., & Bäckvall, J. E. (2016). A Synthesis of Substituted α-Allenols via Iron-Catalyzed Cross-Coupling of Propargyl Carboxylates with Grignard Reagents. ACS catalysis, 6(11), 7448-7451. https://doi.org/10.1021/acscatal.6b02114
Kessler, Simon N, et al. "A Synthesis of Substituted α-Allenols via Iron-Catalyzed Cross-Coupling of Propargyl Carboxylates with Grignard Reagents." ACS catalysis vol. 6,11 (2016): 7448-7451. doi: https://doi.org/10.1021/acscatal.6b02114
Kessler SN, Hundemer F, Bäckvall JE. A Synthesis of Substituted α-Allenols via Iron-Catalyzed Cross-Coupling of Propargyl Carboxylates with Grignard Reagents. ACS Catal. 2016 Nov 04;6(11):7448-7451. doi: 10.1021/acscatal.6b02114. Epub 2016 Sep 28. PMID: 27840771; PMCID: PMC5100686.
Copy Download .nbib Format: NLM
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Oncoimmunology

Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M.
PMID: 27467960
Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May.

Immunomodulation is an important part of lenalidomide's mode of action. We analyzed the impact of lenalidomide on T cells from patients with multiple myeloma during lenalidomide therapy in vivo and in patients with lenalidomide-refractory disease in vitro Patients enrolled...

Cite
Krämer I, Engelhardt M, Fichtner S, et al. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662doi: 10.1080/2162402X.2016.1139662.
Krämer, I., Engelhardt, M., Fichtner, S., Neuber, B., Medenhoff, S., Bertsch, U., Hillengass, J., Raab, M. S., Hose, D., Ho, A. D., Goldschmidt, H., & Hundemer, M. (2016). Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology, 5(5), e1139662. https://doi.org/10.1080/2162402X.2016.1139662
Krämer, Isabelle, et al. "Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro." Oncoimmunology vol. 5,5 (2016): e1139662. doi: https://doi.org/10.1080/2162402X.2016.1139662
Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May. PMID: 27467960; PMCID: PMC4910703.
Copy Download .nbib Format: NLM
COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital.

ANZ journal of surgery

Best OV, Armany D, Murthy V, Handmer M, Mancuso P.
PMID: 34288346
ANZ J Surg. 2021 Dec;91(12):2800-2805. doi: 10.1111/ans.17102. Epub 2021 Aug 02.

BACKGROUNDS: The COVID-19 pandemic is an unprecedented threat to health and healthcare systems. There is no published data on the impact on urological presentations in Australia.METHODS: A retrospective analysis of all admissions under the urology service at Liverpool Hospital,...

Cite
Best OV, Armany D, Murthy V, et al. COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital. ANZ J Surg. 2021;91(12):2800-2805doi: 10.1111/ans.17102.
Best, O. V., Armany, D., Murthy, V., Handmer, M., & Mancuso, P. (2021). COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital. ANZ journal of surgery, 91(12), 2800-2805. https://doi.org/10.1111/ans.17102
Best, Oliver V, et al. "COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital." ANZ journal of surgery vol. 91,12 (2021): 2800-2805. doi: https://doi.org/10.1111/ans.17102
Best OV, Armany D, Murthy V, Handmer M, Mancuso P. COVID-19 had no impact on emergency urological admissions at an Australian tertiary hospital. ANZ J Surg. 2021 Dec;91(12):2800-2805. doi: 10.1111/ans.17102. Epub 2021 Aug 02. PMID: 34288346; PMCID: PMC8420431.
Copy Download .nbib Format: NLM
Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.

Hypertension (Dallas, Tex. : 1979)

Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM.
PMID: 34657442
Hypertension. 2022 Jan;79(1):178-186. doi: 10.1161/HYPERTENSIONAHA.121.18118. Epub 2021 Oct 18.

Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at...

Cite
Hundemer GL, Imsirovic H, Vaidya A, et al. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension. 2021;79(1):178-186doi: 10.1161/HYPERTENSIONAHA.121.18118.
Hundemer, G. L., Imsirovic, H., Vaidya, A., Yozamp, N., Goupil, R., Madore, F., Agharazii, M., Knoll, G., & Sood, M. M. (2022). Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension (Dallas, Tex. : 1979), 79(1), 178-186. https://doi.org/10.1161/HYPERTENSIONAHA.121.18118
Hundemer, Gregory L, et al. "Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study." Hypertension (Dallas, Tex. : 1979) vol. 79,1 (2022): 178-186. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.18118
Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension. 2022 Jan;79(1):178-186. doi: 10.1161/HYPERTENSIONAHA.121.18118. Epub 2021 Oct 18. PMID: 34657442; PMCID: PMC8664996.
Copy Download .nbib Format: NLM
Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.

Hypertension (Dallas, Tex. : 1979)

Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM.
PMID: 34657442
Hypertension. 2022 Jan;79(1):178-186. doi: 10.1161/HYPERTENSIONAHA.121.18118. Epub 2021 Oct 18.

Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at...

Cite
Hundemer GL, Imsirovic H, Vaidya A, et al. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension. 2021;79(1):178-186doi: 10.1161/HYPERTENSIONAHA.121.18118.
Hundemer, G. L., Imsirovic, H., Vaidya, A., Yozamp, N., Goupil, R., Madore, F., Agharazii, M., Knoll, G., & Sood, M. M. (2022). Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension (Dallas, Tex. : 1979), 79(1), 178-186. https://doi.org/10.1161/HYPERTENSIONAHA.121.18118
Hundemer, Gregory L, et al. "Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study." Hypertension (Dallas, Tex. : 1979) vol. 79,1 (2022): 178-186. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.18118
Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension. 2022 Jan;79(1):178-186. doi: 10.1161/HYPERTENSIONAHA.121.18118. Epub 2021 Oct 18. PMID: 34657442; PMCID: PMC8664996.
Copy Download .nbib Format: NLM
[Allergy in dental medicine (II)].

Quintessenz Journal

Hundeiker M.
PMID: 284436
Quintessenz J. 1977 Nov;7(11):13-21.

No abstract available.

Cite
Hundeiker M. Allergie in der Zahnmedizin (II). [Allergy in dental medicine (II)]. Quintessenz J. 1977;7(11):13-21
Hundeiker, M. (1977). Allergie in der Zahnmedizin (II). [Allergy in dental medicine (II)]. Quintessenz Journal, 7(11), 13-21.
Hundeiker, M. "Allergie in der Zahnmedizin (II)." [Allergy in dental medicine (II)]. Quintessenz Journal vol. 7,11 (1977): 13-21.
Hundeiker M. Allergie in der Zahnmedizin (II). [Allergy in dental medicine (II)]. Quintessenz J. 1977 Nov;7(11):13-21. German. PMID: 284436.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 91 entries